Expected Moves

Proceeding from the $0.002 bearish pathway, this update on strategic alternatives and creditor negotiations will dictate whether the equity retains any salvage value toward $0.01 or collapses further to $0.0005.

Anchored at $0.0005, any final attempts to monetize leftover biotechnology patents or clinical assets could spike shares to $0.003, whereas failure to generate cash proceeds will force a final dilution spiral toward absolute zero at $0.0001.